Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jan 28, 2017 10:08am
135 Views
Post# 25767435

RE:The company just tweeted this video....

RE:The company just tweeted this video....ledrog, thanks for posting.

This is a major breakthrough on behalf of RVX in terms of communicatiions.

That being said it is very scientific. I'm sure they had limited time in terms of the length of the video. I would assume that the target market is scientists, perhaps science students and possibly medical specialists. Hopefuly it will create credibility and interest among these groups.

I believe, based on this youtube, that RVX has the potential to develop investor and even patient versions that could be understood by these groups. They could have a version that shows the post hoc findings leading to BETonMACE. In a version like this they could explain the multi-modal impact of apabetalone and explain the meanings and implications of things like inflammation, complement, etc.  It would be very interesting if they could attract media attention.

They could do a version with the recent New Zealand CKD results.

Congrats to RVX communications/IR or who ever created and posted this. Great start! To me it marks a turning point for RVX communications.

Good for RVX. It is a start!
Cheers
Toinv
Bullboard Posts